MedTrace Logo

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

NCT03416231 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-01-31

No results posted yet for this study

Summary

The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.

Conditions

Interventions

DRUG

Apatinib

apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.

DRUG

Docetaxel

Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Affiliated Hospital of North Sichuan Medical College

    lead OTHER

Principal Investigators

  • Daiyuan Ma, M.D · Affiliated Hospital of North Sichuan Medical College

  • xin hu, M.D. · Nanchong Central Hospital

  • xiangdong fang, M.d. · Dazhou Central Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-01-01
Completion
2020-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03416231 on ClinicalTrials.gov